23596-28-3

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI) is utilized as a key intermediate in the development of new drugs. Its unique structure and reactivity make it a promising candidate for the creation of innovative pharmaceuticals with potential therapeutic benefits.
Used in Organic Synthesis:
In the realm of organic synthesis, 1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI) serves as a valuable building block for the synthesis of more complex organic molecules. Its heterocycle nature allows for the formation of various chemical bonds and reactions, contributing to the synthesis of a wide range of organic compounds.
Used in Drug Discovery:
1H-Pyrrolo[3,2-c]pyridine,2,3-dihydro-(8CI,9CI) is employed as a starting material in drug discovery processes. Its properties and potential uses make it an important target for further study and exploration, with the aim of identifying new therapeutic agents and advancing the development of novel pharmaceuticals.

Upstream product

• 219834-81-8 tert-butyl 2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 504-24-5 4-aminopyridine 
• 98400-69-2 N-(4-pyridyl) t-butyl carbamate 
• 219834-80-7 (tert-butoxy)-N-[3-(2-hydroxyethyl)(4-pyridyl)]carboxamide 
• 271-34-1 5-azaindole 

Downstream Products

• 219834-81-8 tert-butyl 2,3-dihydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate 
• 219834-79-4 1-methyl-2,3-dihydro-1H-pyrrolo<3,2-c>pyridine 
• 219834-82-9 7-bromo-1-methyl-2-pyrrolino[3,2-c]pyridine 
• 219834-88-5 1-Methyl-7-(1-naphthyl)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine 
• 279239-02-0 (+/-)-1-methyl-7-(2-methylnaphthyl)-2-pyrrolino[3,2-c]pyridine 
• 219834-89-6 2-methoxy-1-(1-methyl(2-pyrrolino[2,3-d]pyridin-7-yl))naphthalene 
• 219834-97-6 1-(1-methyl-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-7-yl)-naphthalen-2-ol 
• 219834-92-1 1-(1-methyl(2-pyrrolino[2,3-d]pyridin-7-yl))-2-(phenylmethoxy)naphthalene 
• 219834-98-7 1-(1-methyl-2-pyrrolino[2,3-d]pyridin-7-yl)-2-naphthyl (trifluoromethyl)sulfonate 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as in the description, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.

NOVEL COMPOUNDS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.

NOVEL PDE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION

The present invention relates to novel heterocyclic compounds of general formula (I), which are phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors, pharmaceutical compositions containing them, and processes for their preparation. These novel PDEs are useful in treating allergic and inflammatory diseases (such as asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders) and for inhibiting the production of Tumor Necrosis Factor(TNF-α).

Configurationally Stable Biaryl Analogues of 4-(Dimethylamino)pyridine: A Novel Class of Chiral Nucleophilic Catalysts

A short synthetic approach toward a novel class of chiral nucleophilic catalysts, the dissymmetry of which stems from restricted rotation about an Ar-Ar bond, has been developed. The key steps of the synthesis include preparation of a nucleophilic 1-methyl-2-pyrrolino[3,2-c]pyridine core 16 by ortho-lithiation and creation of the biaryl axes via Suzuki cross-coupling reactions. Comparative HPLC studies of racemization for configurationally labile biaryls 31, 38, and 43 containing 1-methyl-2-pyrrolino[3,2-c]pyridine, 4-(dimethylamino)pyridine, and 4-(1-pyrrolidino)pyridine cores, respectively, have demonstrated that a pyrrolidino substituent ortho to the biaryl axis is optimal for slowing Ar-Ar rotation. Biaryls containing all three cores have been shown to retain DMAP-like catalytic activity in the acylation of a hindered alcohol. Biaryls 55 and 56, which are configurationally stable at ambient temperature, have also been prepared via modification of configurationally labile derivatives. Compounds 55 and 56 in optically pure form should provide a useful starting point for studies on catalytic asymmetric acyl transfer using atropisomeric analogues of DMAP.